ROSEN, A HIGHLY RESPECTED LAW FIRM, ENCOURAGES THE INVESTORS OF APPLIED THERAPEUTICS, INC. to secure counsel before an important deadline in the Securities Class Action

New York, New York — (Newsfile Corp. – January 11, 2025) – FOR WHAT: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Applied Therapeutics, Inc. (NASDAQ: NASDAQ: ) between January 3, 2024 and December 2, 2024, both dates inclusive (the “Class Period”), of the relevant February 18, 2025 deadline of the main actor.

SO WHAT: If you purchased securities of Applied Therapeutics during the Class Period, you may be entitled to compensation without payment of any expenses or out-of-pocket expenses through a contingency fee agreement.

WHAT TO DO NEXT: To join the Applied Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=32500 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information about the class action. A class action lawsuit has already been filed. If you want to serve as the main plaintiff, you must move the Court no later than February 18, 2025. A principal plaintiff is a representative party who acts on behalf of the other members of the class in conducting the litigation.

WHY ROSEN LAW: We encourage investors to select qualified advisors with a track record of success in leadership roles. Often, companies issuing notices do not have comparable experience, resources, or significant peer recognition. Many of these firms do not actually litigate securities class actions, but are simply intermediaries who refer clients or partners with law firms that actually litigate cases. Be cautious in selecting counsel. The Rosen Law Firm represents investors around the globe, focusing its practice on securities class actions and shareholder derivative litigation. Rosen Law Firm has obtained the largest securities class action settlement against a Chinese Company at the time. Rosen Law Firm was ranked #1 by ISS Securities Class Action (WA:) Services for the number of securities class action settlements in 2017. The firm has been ranked in the top 4 every year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone, the company secured more than $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 Titan of Plaintiffs’ Bar. Many of the firm’s lawyers have been recognized by Lawdragon and Super Lawyers.

CASE DETAILS: According to the lawsuit, statements made during the class period were false and/or materially misleading because they concealed and misrepresented the clinical trial protocols and procedures that Applied Therapeutics had in place. Therefore, the defendants provided the investors with the false impression that the protocol and good clinical practices were properly followed. The lawsuit alleges that, in fact, Applied Therapeutics was not adhering to the trial protocol and good clinical practices which, in turn, created an excessively severe risk that the trial data would be rejected by the Administration of l Food and Drug Administration of the United States (“FDA”). the context of a new drug request. When the real details entered the market, the lawsuit claims that investors suffered damages.

To join the Applied Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=32500 call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information about the class action.

No Class has been certified. Until a class is certified, you are not represented by an attorney unless you retain one. You can choose the advice of your choice. You can also be an absent class member and do nothing at this point. The investor’s ability to share in any potential future recovery is not dependent on serving as the lead actor.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook (NASDAQ:): https :/ /www.facebook.com/rosenlawfirm.

Attorney Advertising. Previous results do not guarantee a similar result.

——————————–

Contact information:

To view the source version of this press release, visit https://www.newsfilecorp.com/release/236844